Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates.
about
Production and Characterization of Monoclonal Antibodies Specific for a Conserved Epitope within Hepatitis C Virus Hypervariable Region 1Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders.Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines.Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vectorRecognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody.Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infectionCD81-Dependent Binding of Hepatitis C Virus E1E2 HeterodimersInduction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2CD81 Is a Central Regulator of Cellular Events Required for Hepatitis C Virus Infection of Human HepatocytesConserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goatsCapitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine designElicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal modelsDevelopment of hepatitis C virus vaccine using hepatitis B core antigen as immuno-carrier.Development of prophylactic and therapeutic vaccines against hepatitis C virus.Generation of genetically stable recombinant rotaviruses containing novel genome rearrangements and heterologous sequences by reverse genetics.A neutralization epitope in the hepatitis C virus E2 glycoprotein interacts with host entry factor CD81.The ins and outs of hepatitis C virus entry and assembly.Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.In vitro neutralization of HCV by goat antibodies against peptides encompassing regions downstream of HVR-1 of E2 glycoprotein.Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans.Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment.Antibodies to a novel antigen in acute hepatitis C virus infections.Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells.Recombinant Flag-tagged E1E2 glycoproteins from three hepatitis C virus genotypes are biologically functional and elicit cross-reactive neutralizing antibodies in mice.HCV envelope glycoproteins in evirion assembly and entry
P2860
Q27470002-E2DA0054-9A13-4B2A-AE6F-D1BE0DCFE7AFQ27472760-3289C536-E27B-41F1-A1B4-2F4CD717EA7AQ27472837-03B82F35-DE8F-45E8-9DBE-261E44D3D5E2Q27472940-52DA7098-280B-4268-B642-5C6BE348D299Q27473084-40BB8F4C-1E98-4339-AA26-C0D0BA26FA54Q27473382-BA01B37B-F873-488C-BBC9-C135D0E3AD40Q27485659-B3D15EDF-716B-465B-81DF-38797BBEB03EQ27486582-27338FBD-7084-4809-A104-4E78F0E96D8DQ27486789-16F1FB71-E411-4848-88DD-D9F0EF856213Q27488724-57972D5C-F2AB-445E-8993-B9916DC47FB1Q30374314-B480EC32-9135-4906-84A8-884CBCF2ED97Q33867634-9E59DE4C-5A96-4502-8CB9-318BA9430168Q34001755-18FF87A2-0764-427C-8DDE-07AA643FC2CCQ36198667-E6B77F14-CF0E-4008-A7B2-20FB6AC9F3CCQ36827184-0362E3BE-3840-474B-B4A2-4F58A391C02AQ37439266-63849F26-3B3D-4E61-BE45-7EA3601A5CF4Q37498626-6D17D24B-B4B6-4F3C-A3C8-015D86411DE0Q37512845-E95F1CAC-4AEB-4E71-8B7E-E63248B28FEBQ39092410-C7998638-1B9C-4D60-A0AC-97CD94996149Q40261250-377BC68B-C461-4BB3-A7A1-7D49F3EC645DQ40585135-DF74B010-CD4B-4046-AC36-DFFE9204F4BDQ43034612-ED4B1C68-F3EE-47E6-8034-E85FC3327BC4Q45738814-65ACC92F-9B33-4E02-AA6E-EF90D3E0428FQ54239331-BD83A6F1-06E6-4609-9D6E-526907BFB665Q56910948-E7638AAD-1213-49E2-843D-05B6AD7CC0FB
P2860
Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Evaluation of hepatitis C viru ...... d DNA-based vaccine candidates
@nl
Evaluation of hepatitis C viru ...... DNA-based vaccine candidates.
@ast
Evaluation of hepatitis C viru ...... DNA-based vaccine candidates.
@en
type
label
Evaluation of hepatitis C viru ...... d DNA-based vaccine candidates
@nl
Evaluation of hepatitis C viru ...... DNA-based vaccine candidates.
@ast
Evaluation of hepatitis C viru ...... DNA-based vaccine candidates.
@en
prefLabel
Evaluation of hepatitis C viru ...... d DNA-based vaccine candidates
@nl
Evaluation of hepatitis C viru ...... DNA-based vaccine candidates.
@ast
Evaluation of hepatitis C viru ...... DNA-based vaccine candidates.
@en
P2093
P2860
P921
P1433
P1476
Evaluation of hepatitis C viru ...... DNA-based vaccine candidates.
@en
P2093
Abrignani S
Archangel P
Campagnoli S
P2860
P304
P356
10.1128/JVI.74.15.6885-6892.2000
P577
2000-08-01T00:00:00Z